Vidan Diagnostics Launches Next Generation βeta-Hydroxybutyrate Assay on Roche Cobas® Pro C 503

SAN ANTONIO, Texas, August 16, 2021 – Vidan Diagnostics, LLC today announced that it has validated and released its reagent application for its Next Generaton Beta-hydroxybutyrate 21FS Reagent on the Roche cobas^® pro c 503 clinical chemistry system. With cobas® pro integrated solutions, laboratories get answers fast with short and predictable turnaround times. The c 503 analytical unit has 60 reagent positions and yields up to 1,000 test per hour. In addition, the ISE analytical unit will yield up to 900 test per hour. Every effort has been made by Roche to reduce maintenance tasks to a minimum. The new and smart concept of self-operating maintenance executes maintenance tasks automatically in the background and reduces the manual burden of daily maintenance to zero for the cobas^® c 503.

Roche cobas^® pro c 503 and Beta-hydroxybutyrate 21FS

Vidan Diagnostics’ β-Hydroxybutyrate 21FS assay offers 70 days calibration and onboard stability and a linear range up to 6.0 mmol/L. “We have seen many laboratories transition to the new Roche cobas^® c 503”, said Gilbert Mejia, CEO of Vidan Diagnostics. In order to make the transition easier for our customers, it was necessary to validate our reagent application on the c 503. Based on the results of our validated reagent application for our next generation beta-hydroxybutyrate assay, our Roche customers can clearly see our advantages over our competitors.”, Mejia added.

Beta-Hydroxybutyrate

Beta-Hydroxybutyrate (BHB) is an important marker when used in conjunction with clinical findings and other laboratory tests for the diagnosis and management of ketoacidosis and its main causative factor, diabetic ketoacidosis (DKA).

Beta-hydroxybutyrate is the predominate ketone body produced during Diabetic Ketoacidosis, (DKA) It’s relative proportion in the blood, (78%) is greater than the other two ketones, acetoacetate, (20%) and acetone, (2%) and is therefore the best indicator of DKA. DKA is a serious condition that can lead to diabetic coma or even death.

Founded in 2018, Vidan Diagnostics LLC is a supplier of medical diagnostic products. It is focused on medical devices and reagents used for diagnosing and monitoring patients with conditions of diabetes, sepsis, anemia, heart disease and stroke. Vidan Diagnostics is dedicated to delivering proven and innovative products to all people in all places, in all aspects and stages of life with integrity and reliability. The company is headquartered in San Antonio, Texas.